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Abstract: Pectenotoxin-2 (PTX-2), which was first identified as a cytotoxic entity in 
marine sponges, has been reported to display significant cytotoxicity to human cancer cells 
where it inhibits mitotic separation and cytokinesis through the depolymerization of actin 
filaments. In the late stage of endoreduplication, the effects of PTX-2 on different cancer 
cells involves: (i) down-regulation of anti-apoptotic Bcl-2 members and IAP family 
proteins; (ii) up-regulation of pro-apoptotic Bax protein and tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL)-receptor 1/receptor 2 (DR4/DR5); and (iii) mitochondrial 
dysfunction. In addition, PTX-2 induces apoptotic effects through suppression of the 
nuclear factor κB (NF-κB) signaling pathway in several cancer cells. Analysis of cell cycle 
regulatory proteins showed that PTX-2 increases phosphorylation of Cdc25c and decreases 
protein levels of Cdc2 and cyclin B1. Cyclin-dependent kinase (Cdk) inhibitor p21 and 
Cdk2, which are associated with the induction of endoreduplication, were upregulated. 
Furthermore, it was found that PTX-2 suppressed telomerase activity through the 
transcriptional and post-translational suppression of hTERT. The purpose of this review 
was to provide an update regarding the anti-cancer mechanism of PTX-2, with a special 
focus on its effects on different cellular signaling cascades.  
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1. Introduction  
The pectenotoxins (PTXs) are macrolactones with multiple polyether ring units, which depolymerize 
actin filaments [1,2]. The ability of these PTXs to interfere with actin cytoskeleton dynamics allows 
them to play important roles as precursor molecules in chemotherapy. Moreover, their potential utility 
in the treatment of cancer has been recognized [3]. Among them, pectenotoxin-2 (PTX-2, Figure 1), 
which was first identified as a cytotoxic entity in marine sponges, was found to be highly effective and 
more potent against several cancer cell lines and its biological and functional mechanisms have been 
intensively investigated. In particular, many in vitro and biochemical studies have shown that PTX-2 
inhibits actin polymerization in a concentration-dependent manner. It does not affect tubulin, which is 
another molecule that regulates mitotic separation and cytokinesis [1]. First, a study found that   
actin stress fibers were disrupted by PTX-2. Further, PTX-2 inhibited the velocity and the degree of 
pyrenyl-actin polymerization as well as the viscosity of F-actin in a concentration dependent   
manner [4–6]. These results suggest that PTX-2 is a potent actin depolymerizing agent, which suggests 
that it might be a potent anti-cancer agent possessing a unique mode of action. 
Actin is one of the most abundant and common cytoskeletal proteins for cell growth, motility, 
signaling, and maintenance of cell shape. Because PTX-2 affects actin polymerization, many studies 
have been done on the effect of PTX-2 on cell cycle arrest, endoreduplication, and apoptosis, as well 
as on its anti-inflammatory effects. The rest of the review will discuss the effect of PTX-2 on the above 
phases by relating PTX-2 to different cellular signaling cascades.  
Figure 1. Chemical structure of PTX-2 (A), Molecular Weight: 859.1; Molecular Formula: 
C47H70O14 and confocal imaging of actin cytoskeleton and morphology of hepatic cells (B). 
Panels (a) and (c) are fluorescence and transmission photographs of the control cells, 
respectively; panels (b) and (d) are from cells treated with 200 nM PTX-2. Arrows point to 
differences on the F-actin distribution between control and treated cells (bundles and dots, 
respectively). One cell is outlined in controls (c) and in cells incubated with PTX-2 (d) to 
show morphological changes. Images are representative of three independent experiments. 
Scale bar = 50 μm [6].  
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Figure 1. Cont. 
 
2. Effect of PTX-2 on Cell Cycle Arrest and Endoreduplication 
In this section, we explain the effects of PTX-2 on cell cycle arrest as well as endoreduplication.  
It is well established that PTX-2 strongly induces cell cycle arrest at G2/M phase in different   
cancer cells. It is further shown that this potent agent induces endoreduplication in a manner that is 
independent of cell type.  
2.1. G2/M Phase Cell Cycle Arrest 
Cell cycle arrest is one of the key factors of an effective chemopreventive agent. Many other data 
show that PTX-2 possesses strong anti-proliferative properties in various cancer cell lines. In particular, 
PTX-2 prevented the proliferation of cancer cells by interfering with various stages of cell cycle 
progression. In the first part of this section, we will discuss how PTX-2 interferes with cell cycle 
progression through G2/M phase. Recently, we reported that PTX-2 significantly caused G2/M phase 
arrest in several human cancer cell lines [7,8]. Further experimental results indicated that not only 
leukemia cells but also human hepatoma cells and breast cancer cells suffered cell cycle arrest at the 
same stage. In these studies, PTX-2 increased phosphorylation of Cdc25C and decreased protein levels 
of Cdc2 (Cdk1, cyclin-dependent kinase 1), cyclin B1; and the M phase-specific marker protein, 
phospho-histone 3 was markedly increased by PTX-2 [7]. Moreover, induction of G2/M phase arrest 
by PTX-2 was regulated by the extracellular signal-regulated kinase (ERK) and by the c-jun   
N-terminal kinase (JNK) pathway. 
It is well known that Cdc25C directs dephosphorylation of cyclin B-bound Cdc2 and triggers entry 
into mitosis [9]. However, cancer cells show abnormal growth patterns due to deregulation of 
these  proteins. Activated Cdc25C is dissociated from 14-3-3 proteins, phosphoserine- or   
phosphothreonine-binding proteins, which are involved in a variety of cellular processes, including Mar. Drugs 2011, 9                 
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gene regulation, differentiation, cell cycle progression, and metabolism, at the G2/M transition. At the 
same time, Cdc25C undergoes hyperphosphorylation on several sites within its regulatory N-terminal 
domain, an effect mediated by Cdks and polo-like kinase 1 (Plk1) [10]. Sanchez et al. [11] reported 
that increased Cdc25C’s phosphatase activity could lead to the activation of Cdc2/cyclin B, which 
results from the dephosphorylation of Cdc2 by Cdc25C. On the other hand, phosphorylation at serine 
216 induces the cytosolic retention of Cdc25C through 14-3-3 binding [12]. This is a good strategy for 
blocking or delaying entry into mitosis. Therefore, as we expected, PTX-2-induced G2/M phase arrest 
is associated with the repression of Cdc2 and cyclin B1 expression, and with the induction of the 
phosphorylation of Cdc25C at ser-216 [7]. 
In another experiment, we investigated PTX-2-induced cell cycle arrest at G2/M phase in human 
breast cancer cells via ATM (ataxia-telangiectasia-mutated) and Chk1/2 (checkpoint kinases 1/2)-mediated 
phosphorylation of Cdc25C [13]. As mentioned above, phosphorylation at serine 216 induces the 
cytosolic retention of Cdc25C through binding to 14-3-3 in response to DNA damage [12]. Therefore, 
cell cycle checkpoints play an important role in safe guarding genomic DNA errors that may occur 
during chromosome segregation and DNA replication [11]. The activation of checkpoints that are 
responsive to DNA damage or incomplete DNA replication ultimately results in the inhibition of 
cyclin-dependent kinases. Chk1 and Chk2 can be activated in response to DNA damage through 
phosphorylation on ser-345/ser-317 and Thr-68, respectively. Cdc25, when phosphorylated on serine 
216 by activation of Chks, thus blocks downstream Cdc activation and mitosis. According to Singh’s 
study, human cancer cell-derived Chk2(−/−) cells were significantly more resistant to G2/M arrest than 
Chk2(+/+) cells [14]. Our data show that phosphorylation of Chks was increased by PTX-2 in a 
concentration dependent manner [13]. It is well known that ATM phosphorylates several key proteins 
such as p53 and Chks that initiate activation of the DNA damage checkpoint, leading to cell cycle 
arrest or apoptosis. Therefore, our study shows that PTX-2-treated cells markedly increase the   
serine-216 phosphorylation of Cdc25C that is associated with ATM dependent activation of Chks [13]. 
Furthermore, Cdc25 phosphatase prevents entry into mitosis and stabilizes the tumor suppressor 
protein p53, leading to cell cycle arrest. However, PTX-2-induced G2/M arrest was not significantly 
different between MDA-MB-231, which contains the mutant p53 gene, and MCF-7 cells, which 
expresses the wild-type p53 gene, indicating that p53 is independent of G2/M arrest induced by   
PTX-2 [13].  
2.2. Endoreduplication  
Based on experiments on a broad spectrum of cell types in which endoreduplication occurs,   
many hypotheses have been generated to explain the functional importance of this phenomenon. 
Endoreduplication can be understood simply as a variant form of the mitotic cell cycle in which 
mitosis is aborted prior to cytokinesis due in part to modulation of cyclin-dependent activity. However, 
many aspects of cell cycle control require negative regulation of Cdks. Negative regulation of Cdk 
activity is achieved either by phosphorylation of the catalytic subunit or via the binding of Cdk 
inhibitory proteins known as CKIs [15]. The other mechanism is via disruption of the actin 
cytoskeleton by extracellular agents, which can affect cell growth, motility, signaling, and maintenance 
of cell shape [1]. Recent studies have investigated whether the binding and stabilizing of actin Mar. Drugs 2011, 9                 
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microfilaments using actin polymerization inhibitors can inhibit the growth of several tumor cell   
lines [16]. Thus, cytotoxic agents have been shown to play important roles in anti-cancer therapy due 
to their ability to interfere with actin cytoskeleton dynamics, and their potential utility in the treatment 
of cancer has been recognized. 
In particular, PTX-2 has been shown to have a potent cytotoxic effect in human cancer cell lines. 
Recent studies have also demonstrated that the anti-cancer effect of PTX-2 is due to disruption of the 
actin cytoskeleton through the inhibition of actin polymerization, in vitro and in vivo [17]. We 
experimentally found that PTX-2 treatment decreases the fluorescence intensity of phalloidin-FITC in 
a dose-dependent manner in human leukemia U937 cells [7]. This indicates that PTX-2 causes a 
decrease in cell proliferation through the depolymerization of actin. Additionally, maintenance of 
constant cell size during cellular proliferation must be coordinated with the rate of cell division. The 
failure of mitotic cell division caused by PTX-2 is associated with an increase in cell size, and this 
phenomenon is exhibited by PTX-2 when 10 ng/mL of PTX-2 treatment is done for 72 h in leukemia 
cells; this contributes to an increase in cell size. 
Microtubules are present in cell cytoskeletal networks, and play important roles in many aspects of 
the fundamental processes of cell growth and development including cell division, cell expansion, 
intracellular organization, and cell motility [18]. It is known that disruption of the dynamics of 
microtubule polymerization induces endoreduplication. However, we experimentally found that PTX-2 
did not change tubulin polymerization in vitro, whereas induction of the formation of giant cells   
by PTX-2 in leukemia cells could promote the synthesis of a large amount of α-tubulin [7].   
A recent study has also shown that the increased expression of Cdk2 and p21 is associated with 
endoreduplication [19]. Since Cdk2 is essential for the G1/S transition, consistent or overexpressed 
Cdk2 in G2/M arrested cells could induce endoreduplication through a re-entry into S phase. 
Interestingly, p21 and Cdk2 protein levels increased significantly in response to PTX-2 [7]. Thus, 
PTX-2 induces G2/M phase arrest and endoreduplication via the modulation of cell cycle-regulating 
proteins. One of the signaling pathways that can control the cell cycle is the mitogen-activated protein 
kinase (MAPK) signaling cascade. Actin dysfunction accelerates the ERK and the JNK signal 
pathways, and delays entry into mitosis in mammalian cells [20,21]. PTX-2 significantly induced the 
phosphorylation of ERK, JNK, and p38MAPK. Further data showed that the ERK and JNK signaling 
pathways are involved in PTX-2-induced actin dysfunction, suggesting the presence of an actin 
checkpoint at the G2/M transition in leukemia cells [7]. Not only that, endoreduplication of cancer cell 
lines was induced by this chemical in several types of cancer cells in vitro. Thus PTX-2 induced 
endoreduplication through different cell signaling pathways and promoted actin depolymerization, and 
disrupted the organization of the actin cytoskeleton. 
2.3. Effect of PTX-2 on NF-κB and Its Related-Gene Products  
Cell signaling has been most extensively studied in the context of human diseases where it is related 
to proliferation, survival and transformation of cells. These processes have been deeply investigated in 
current studies in cancer biology [22]. Components of signaling networks, include several kinases—such 
as serine/threonine protein kinase, tyrosine-specific protein kinases, histidine-specific protein kinases 
and phosphoinositide-3-kinase—that maintain the metabolic function of cells [23]. Abnormal Mar. Drugs 2011, 9                 
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activation of these kinases or their downstream transcription factors may result in uncontrolled cell 
growth, thus forming a malignant mass. The activation of distinct sets of transcription factors by 
numerous intracellular signaling pathways may cause dysregulation of numerous cell functions. 
Among them, NF-κB plays a key role in cellular signal transduction systems by regulating the   
immune response to infection [24]. However, improper regulation of NF-κB has been linked to 
inflammatory and autoimmune diseases, cancer, septic shock and viral infection [25]. Therefore, over 
the last few decades, many chemopreventive agents have been investigated as inhibitors of NF-κB 
activation pathways. 
NF-κB can be activated by cytokines, bacterial toxins, viral products, oxidative stress, toxic metal 
and UV light, etc. [26]. Activation of NF-κB by these extracellular stimuli leads to the nuclear 
translocation of NF-κB complex, especially the p65 and p50 subunits. NF-κB binds to specific 
sequences of the DNA promoter region. This DNA/NF-κB complex then recruits other proteins and 
ends up causing expression of different translated proteins including cell proliferation proteins, cell 
cycle regulating proteins, and proteins that regulate apoptosis [27]. Chemopreventive agents that block 
NF-κB pathways are used to understand the mechanism of inhibiting NFKB activity in different cancer 
cell lines. Thus, we have recorded the effect of PTX-2 on constitutive NF-κB activity and NF-κB 
regulated gene expression in human leukemia cancer cells [28]. We found that PTX-2 inhibits 
constitutive and induced expression of NF-κB activated genes. A number of reports have demonstrated 
that NF-κB activation can maintain tumor cell viability and that inhibiting NF-κB activity alone can be 
sufficient to induce cell death. On the other hand, active NF-κB turns on the expression of genes that 
keep the cell proliferating and protect the cell from conditions that would otherwise cause it to die via 
apoptosis [26]. It has been confirmed that several NF-κB inhibitors act as potent enhancers of 
chemotherapy, inducing apoptosis in various cancer cells. One of our studies showed that PTX-2 
significantly inhibits constitutive and induced NF-κB, leading to blockage of the IκB proteolytic 
pathway in vitro [28]. Therefore, NF-κB plays an important role in the cytotoxicity of PTX-2 because 
NF-κB causes many genes to induce cell proliferation, cell survival and apoptosis. As such, many 
different types of human tumors have dysregulated NF-κB that is constitutively active. Our studies 
further show that NF-κB involvement in proliferation (Cox-2) and anti-apoptosis (IAP-1, IAP-2 and 
XIAP) are significantly inhibited by PTX-2 treatment. Therefore, PTX-2 can downregulate NF-κB 
dependent anti-apoptotic gene products.  
3. Effect of PTX-2 on Apoptosis 
Programmed cell death is a key process in cancer development and progression. The ability of 
cancer cells to avoid apoptosis and to continue to proliferate is one of the fundamental characteristics 
of cancer and is a major target in the development of new cancer therapies [29]. Therefore, apoptosis 
plays an important role in regulating the number of cells in both human embryonic development and 
adult tissue homeostasis. Apoptotic cells are characterized by several unique features including nuclear 
fragmentation, chromatin condensation, blebbing, loss of cell membrane asymmetry and attachment, 
cell shrinkage and chromosomal DNA fragmentation [29,30]. The process of apoptosis is controlled by 
a diverse range of cell signals that can originate either extracellularly or intracellularly, known as the 
extrinsic (death receptor-mediated) and intrinsic (mitochondrial-mediated) pathways, respectively. Mar. Drugs 2011, 9                 
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Extracellular signaling molecules may either cross the plasma membrane or have their presence 
transduced. In both cases they cause an intracellular response and a cell initiates intracellular apoptotic 
signaling in response to stress [31,32]. These signals may positively or negatively affect apoptosis. 
Inhibition of apoptosis can result in a number of cancers, autoimmune diseases, inflammatory diseases, 
and viral infections. Accumulating data indicate that many chemopreventive and/or chemotherapeutic 
agents can cause tumor cell death through the induction of apoptosis. Therefore, the induction of 
apoptotic cell death is an important mechanism in the anticancer properties of many anti-cancer drugs. 
Many studies have reported correlations between drug responsiveness and tumor genotypes. As the 
p53 gene is inactivated in the majority of human cancers, the p53 gene plays a major role in preventing 
tumorigenesis. It does this by responding to both cellular stress and DNA damage. Much effort has 
therefore been made to determine the effects of p53 inactivation on cancer cell responses to therapeutic 
agents [33]. Since NF-κB has also been shown to play a role in tumorigenesis via its constitutive 
activation within a wide variety of tumor types, inhibiting NF-κB activation alone can be sufficient to 
induce cell death [27]. Additionally, Akt is known to activate IKK, which immediately leads to NF-κB 
activation and cell survival. Akt can phosphorylate BAD on Ser136, which makes BAD dissociate 
from the Bcl-2/Bcl-X complex and lose its pro-apoptotic function [33,34]. Therefore, Akt inhibitors 
have been thought of as good candidates for anti-cancer drugs. Several reports have shown that NF-κB 
inhibitors act as potent enhancers of chemotherapy-induced apoptosis. Likewise, PTX-2 was reported 
to be an apoptotic agent in many cancer cell lines because it inhibited expression of many   
anti-apoptotic genes. 
PTX-2 inhibits the expression of anti-apoptotic and proliferative genes known to be regulated by 
NF-κB activity. One of our studies showed that PTX-2 significantly inhibits constitutive NF-κB 
activity, leading to blockage of IκB proteolytic pathways in leukemia cells [28]. Suppression of 
nuclear translocation of NF-κB by the NF-κB inhibitor PDTC enhanced PTX-2-induced apoptosis. 
Also, PTX-2-induced apoptosis may be related to down-modulation of the anti-apoptotic protein   
Bcl-xL as well as to up-regulation of the pro-apoptotic protein Bax. The anti-apoptosis proteins AP-1, 
IAP-2 and XIAP were significantly inhibited by PTX-2 treatment. Therefore, PTX-2 sensitizes 
apoptosis through suppression of NF-κB activity via inactivation of Akt. 
Shin et al. [35] reported that PTX-2 caused proteolytic activation of caspases such as caspase-3, -8 
and -9 in Hep3B cells, though not in HepG2 cells. This compound also downregulated the expression 
of IAP family proteins that are inhibitors of caspases such as XIAP, cIAP-1 and cIAP-2. These data 
indicated that caspase-3 plays an important role in PTX-2-induced apoptosis in p53-deficient Hep3B 
cells. PTX-2 also induced increases in levels of DR4 and DR5; the increase in DR4/5 and Bax levels 
probably contributed to the activation of caspase-8 in Hep3B cells. 
Many studies have demonstrated that p53 directly activates the transcription of a number of genes 
including genes for: (i) the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1), the major mediator of 
p53 cell-cycle inhibitory capacity; and (ii) apoptotic genes [36]. We found that PTX-2 activates an 
intrinsic pathway of apoptosis in p53-deficient tumor cells compared to those with functional p53 both 
in vitro and in vivo [35,37]. Another experiment showed that apoptosis induced by PTX-2 in Hep3B 
cells was associated with modulation of the Bcl-2 family, activation of caspases, and loss of the 
mitochondrial membrane potential [37]. Though PTX-2 induced apoptosis in p53-deficient Hep3B 
cells, HepG2 cells were much more resistant to PTX-2, which suggests that PTX-2 acts by a cytotoxic Mar. Drugs 2011, 9                 
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mechanism that is p53-independent. Another study showed the same phenomenon in mitochondria 
integrates death signals through Bcl-2 family members [28]. Release of cytochrome c and smac causes 
caspase activation through the loss of membrane potential and increasing the permeability of the outer 
membrane. This mitochondrial apoptosis pathway is involved in the apoptosis induced by abnormalities 
in actin dynamics. All of these data indicate that Bcl-2 family proteins are dysregulated in p53
−/− cells. 
Therefore, the above data show that PTX-2 induces apoptosis in diverse ways: affecting NF-κB 
proteins and caspases, and changing the mitochondrial potential through suppression of actin 
polymerization (Figure 2). 
Figure 2. Schemes of PTX-2-induced G2/M arrest, endoreduplication, and apoptosis in 
cancer cell lines. MF means Microfilament. 
 
4. Effect of PTX-2 on Telomerase Activity  
Telomeres are repetitive DNA sequences located at the termini of linear chromosomes which are 
responsible for maintaining chromosomal stability [38]. As human telomeres grow shorter, cells 
eventually reach the limit of their replicative capacity and progress into senescence. However, when 
cells begin to become cancerous, they divide more often and its telomeres do not shorten [39]. The 
enzyme known as telomerase can prevent this activity by elongating telomeres. Therefore, this enzyme 
offers an attractive target for chemoprevention and other anticancer strategies. 
The telomerase ribonucleoprotein complex consists of two essential components, a catalytic protein 
subunit human telomerase reverse transcriptase (hTERT), and a template RNA (hTR) [40]. hTR is 
present in all cell types, while hTERT mRNA is not detected in telomerase-negative cells but is present 
in germinal and cancer cells. The promoter region of hTERT contains E-boxes and GC-boxes, the 
consensus binding sequences for Myc and Sp1, respectively [41]. Myc and Sp1 activate hTERT 
transcription by binding to the promoter region and causing cell proliferation. Post-transcriptional and 
translational modifications are tightly controlled by the activity of hTERT. Therefore, hTERT has 
received considerable attention for its role in regulating telomerase activity. Mar. Drugs 2011, 9                 
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Thus, many studies have focused on telomerase activity, studying hTERT and different anticancer 
agents. According to our findings, PTX-2 suppressed telomerase activity in human leukemia cells via 
the transcriptional downregulation of hTERT through reductions in c-Myc and Sp1 activities [42]. 
Akt1 is involved in cellular survival pathways by inhibiting apoptotic processes. Akt phosphorylation 
can also be a potent inducer of telomerase activation via hTERT phosphorylation linked to nuclear 
localization. Our previous data indicated that PTX-2 downregulated p-Akt and the phosphorylation and 
translocation of hTERT [42]. Thus PTX-2 treatment regulates hTERT at the post-translational level by 
downregulating its phosphorylation by the Akt pathway [43]. Finally PTX-2 can act as an inhibitor of 
telomerase activity via the transcriptional and post-translational suppression of hTERT (Figure 3). 
Figure 3. Putative apoptosis mechanism induced by PTX-2 treatment. PTX-2 induces 
apoptosis of cancer cells via increasing ROS generation, inactivation of the NF-kB 
signaling pathway and inhibition of telomerase activity. 
 
5. Conclusion 
Cancer is the uncontrolled growth of cells coupled with malignant behaviors such as invasion and 
metastasis. Most commonly, chemotherapy drugs have been applied to cancer treatment during the 
past few decades. These chemotherapeutic drugs can affect different stages of cell functions and lead 
to cell death. This review is a refresher on the anti-cancer effects of PTX-2 on different cancer cells. 
PTX-2 regulates the behaviors of cancer cells through different cell signaling pathways. Therefore, this 
chemical has good potential to be used as an anticancer drug in the future. So, it is now necessary to 
conduct further research to investigate the anti-cancer properties of this chemical and then to determine 
whether it is safe and effective as an anti-cancer drug. 
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